- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ajovy significantly reduces depressive symptoms of and migraine days in patients with migraine and depression: Phase 4 study
Israel: Ajovy significantly reduced monthly migraine days, and depression symptoms, and brought a sustained reduction in disability in a phase 4 study, UNITE. The drug could ease the cumulative burden of depression and migraines.
The findings from the study were presented on October 17, 2023, at the World Congress of Neurology in Montreal, Canada.
Depression is among the most prevalent psychiatric co-morbidities in migraine and patients with comorbid depression experience an increased risk of migraine ‘chronification’. This is characterized by a greater degree of headache disability, an increase in the number of headache days, a poorer response to migraine treatments, and reduced quality of life.
Ajovy (fremanezumab) is a humanized monoclonal antibody (mAb) developed by Teva Pharmaceuticals that selectively targets the calcitonin gene-related peptide (CGRP), and is approved for migraine prevention in adults who have at least 4 migraine days per month.
Study lead author Richard Lipton M.D., Department of Neurology, Psychiatry and Behavioural Sciences at Albert Einstein College of Medicine, New York said in a press release: “Depression is commonly associated with migraine, and clinicians are increasingly aware of the impact of co-morbidities. We are moving towards more personalised treatment decisions in migraine which are tailored to the patient’s profile, and treatments need to demonstrate efficacy and safety in migraine patients with this particular co-morbidity.”
UNITE is a double-blind, randomised, placebo-controlled, Phase 4 study sponsored by Teva Pharmaceutical investigating the safety, efficacy, and impact of fremanezumab on patients with major depressive disorder and migraine.
The key findings of the trial are as follows:
- Patients in the study treated with fremanezumab experienced a significant reduction in Monthly Migraine Days (MMD) compared to patients on placebo, with a reduction in MMD of –5.1 vs –2.9 for fremanezumab vs placebo.
- On the Hamilton Rating Scale for Depression, the mean score change at week 12 was –6.7 for those treated with fremanezumab and –5.4 for placebo. On the Patient Health Questionnaire-9, the mean changes were –7.8 and –6.3, respectively.
- A significantly higher number of patients (33%), receiving fremanezumab achieved ≥50% reduction in MMD compared to placebo (13%) during the 12-week double-blind period, with a sustained reduction over the longer-term.
- At week 12, participants’ mean change in Headache Impact Test score was –8.8 and –5.2 for fremanezumab and placebo, respectively, and the mean change in Clinical Global Impression-Severity score was –1.1 and –0.8
The results suggest fremanezumab “has the potential to reduce the symptoms and cumulative burden of migraine and associated depression,” the company said in the release.
MBBS, MD Obstetrics and Gynecology
Dr Nirali Kapoor has completed her MBBS from GMC Jamnagar and MD Obstetrics and Gynecology from AIIMS Rishikesh. She underwent training in trauma/emergency medicine non academic residency in AIIMS Delhi for an year after her MBBS. Post her MD, she has joined in a Multispeciality hospital in Amritsar. She is actively involved in cases concerning fetal medicine, infertility and minimal invasive procedures as well as research activities involved around the fields of interest.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751